Clinical features of patients before treatment with hydrochlorothiazide and amiloroide
| Case | Age1-150(months) | Serum sodium (mmol/l) | Serum potassium (mmol/l) | 24 h urine volume (ml/kg bw) | 24 h urine osmolality (mmol/l) | Urine osmolality before DDAVP (mmol/l) | Urine osmolality after DDAVP (mmol/l) | Plasma AVP (pg/ml)†‡ | Genetic mutation of V2 receptor gene |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 6 | 161 | 4.7 | 384 | 83 | 128 | 135 | 3.25 | |
| 2 | 5 | 160 | 4.7 | 360 | 89 | 190 | 210 | Point mutation ( T975 →A) | |
| 3 | 14 | 166 | 6.1 | 432 | 118 | 64 | 152 | 3.0 | Point mutation ( T727 →G)14 |
| 4 | 33 | 145 | 5.8 | 336 | 82 | 82 | 105 | 3.1 | Point mutation ( T727 →G)14 |
↵1-150 At onset of treatment. †While normally rehydrated.‡Reference values mean (SD) 1.1 (0.6) pg/ml.15